Cingulate (CING) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

CING Cingulate

Watchlist

4.6600
+0.0100+0.22%

Trading Nov 22 10:18 ET

14.97MMarket Cap-107P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Cingulate Analyst Ratings
BenzingaNov 20 10:59 ET · Ratings
Maxim Group Upgrades Cingulate(CING.US) to Buy Rating, Announces Target Price $8
Moomoo NewsNov 20 08:31 ET · Ratings
Express News | Cingulate Inc : Maxim Group Raises to Buy From Hold
ReutersNov 20 07:34 ET
10-Q: Q3 2024 Earnings Report
SECNov 7 07:58 ET · Announcements
8-K: Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market
SECNov 7 07:48 ET
Express News | Cingulate Q3 Net Loss $3.2M
BenzingaNov 7 07:41 ET

Comments

Stock_Drift

Yesterday 00:26

Low Floats 11:25am

$Sharps Technology (STSS.US)$ $Verb Technology (VERB.US)$ $High Roller Technologies (ROLR.US)$ $Iveda Solutions (IVDA.US)$ $Cingulate (CING.US)$ $Star Equity (STRR.US)$ $Jowell Global (JWEL.US)$ $Cyclerion Therapeutics (CYCN.US)$ $Digital Ally (DGLY.US)$ $FOUNDER GROUP LIMITED (FGL.US)$ $Silexion Therapeutics (SLXN.US)$ $Exicure (XCUR.US)$ $Forte Biosciences (FBRX.US)$
📊⚡️📊

Stock_Drift

Nov 11 13:04

Low Floats…2:02pm

$Revelation Biosciences (REVB.US)$ $Nukkleus (NUKK.US)$ $Lm Funding America (LMFA.US)$ $Sonoma Pharmaceuticals (SNOA.US)$ $Vertical Aerospace (EVTL.US)$ $Advent Technologies (ADN.US)$ $Avalon Holdings (AWX.US)$ $LakeShore Biopharma (LSB.US)$ $Vicarious Surgical (RBOT.US)$ $Protagenic Therapeutics (PTIX.US)$ $Cingulate (CING.US)$ $BTC Digital (BTCT.US)$ $SemiLEDs (LEDS.US)$ $SU Group Holdings (SUGP.US)$
📊⚡️📊

MrSuperStonk

Nov 7 12:55

$Cingulate (CING.US)$ i will keep my eyes on this one

Jaguar8

Nov 7 07:04

NEWS

$Cingulate (CING.US)$
Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market
Positive
Working capital increased by $19.5M from December 2023
Raised $12.5M in capital during Q3 2024
Net loss decreased by 46% YoY to $3.2M
R&D expenses reduced by $2.5M YoY
Secured European patents for CTx-1301 in up to 30 territories
Regained Nasdaq compliance with $1.00 minimum bid requirement
Negative
Accumulated deficit increa...